[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100411217":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":43,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":7,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Yale University","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Usual diet and physical activity","Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD",[13],{"name":14,"affiliation":15,"role":16},"Nicola Santoro, MD, PhD","Associate Professor of Pediatrics (Endocrinology)","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Ermena REFUGJATI","CONTACT","2032157119","ermena.refugjati@yale.edu",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Yale New Haven Hospital","RECRUITING","New Haven","Connecticut","06510","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-72.92816,41.30815,{"lat":36,"lon":35},[39,42],{"name":40,"role":20,"phone":41,"phoneExt":7,"email":22},"Ermena Refugjati","203-215-7119",{"name":14,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":44,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[46],{"name":47,"class":48},"National Institute on Minority Health and Health Disparities (NIMHD)","NIH","100411217","pathogenesis-of-pediatric-nonalcoholic-fatty-liver-disease-nafld-100411217",false,"NCT04634643","Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)","Pathophysiologic Mechanisms Leading to Intrahepatic Fat Accumulation in Obese Youth","Inclusion Criteria:\n\n* Good general health, taking no medication on a chronic basis;\n* age 12 to 18 years, in puberty (girls and boys: Tanner stage II-V);\n* BMI \\>85th for obese cohort;\n\nExclusion Criteria:\n\n* Baseline creatinine \\>1.0 mg; pregnancy;\n* the presence of endocrinopathies (e.g. Cushing syndrome);\n* cardiac or pulmonary or other significant chronic illness;\n* adolescents with a psychiatric disorder or with substance abuse;\n* monogenic obesity syndromes;\n* use of drugs affecting intrahepatic fat content (e.g.; liraglutide, fish oil, etc.).","ALL","12 Years","18 Years",{"count":60,"type":61},260,"ESTIMATED","OBSERVATIONAL","The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.",[65],"NAFLD","2026-07-28",{"date":68,"type":69},"2026-07-30","ACTUAL",{"date":71,"type":69},"2021-06-28",{"date":73,"type":61},"2027-01-30",{"name":5,"class":6},1]